Table 4.

Details of primary tumor diagnoses, prior palliative treatments, and response data in patients with SCCHN

Patient	Reovirus dose	Disease site	Previous treatments	Response to previous treatments	No. of cycles of trial medication	RECIST response	Clinical response
0102	3 × 109	Oropharynx	CDDP/5-FU (6 cycles)	CR	8	NE (assessable disease in previously irradiated region)	Major clinical response (complete resolution of cutaneous nodules)
0303	3 × 1010	Larynx	CDDP/Cape/Epi (1 cycle)	PD	2	PD	N/A
2003	3 × 1010	Oropharynx	CDDP/5-FU (6 cycles)	PR	8	PR	N/A
			CDDP/5-FU (6 cycles)	PD
			Zalutumumab (2 cycles)	PD
2004	3 × 1010	Hypopharynx	CBCDA/5-FU (6 cycles)	PD	2	PD	N/A
2006	3 × 1010	Larynx	CDDP/5-FU (4 cycles)	PR	5	PR	N/A
			CDDP/5-FU (2 cycles)	PD
2007	3 × 1010	Hypopharynx	CDDP/5-FU (2 cycles)	PD	1	NE (death due to disease progression before 2 cycles)	N/A
2008	3 × 1010	Oral cavity	CDDP/5-FU (4 cycles)	CR	6	PR	N/A
			CDDP/5-FU (4 cycles)	PR
			CBCDA/5-FU (3 cycles)	PD
2011	3 × 1010	Oropharynx	CDDP/5-FU (6 cycles)	PD	1	NE (death due to disease progression before 2 cycles)	N/A
2013	3 × 1010	Oropharynx	CDDP/5-FU (3 cycles)	PD	4	SD	N/A
2014	3 × 1010	Oropharynx	CDDP/RT	PD	1	NE (treatment stopped because of SAE before 2 cycles)	N/A
2015	3 × 1010	Oral cavity	CBCDA/Cape (2 cycles)	PD	6	SD	N/A
2016	3 × 1010	Hypopharynx	CDDP/RT	PD	6	NE (assessable disease in previously irradiated region)	Major clinical response (complete resolution of skin nodules, Fig. 2I and J)
2018	3 × 1010	Oropharynx	CDDP/5-FU (6 cycles)	PR	8	SD	N/A
2019	3 × 1010	Oropharynx	CDDP (6 cycles)	CR	1	NE (treatment stopped because of SAE before 2 cycles)	N/A
			Methotrexate (4 cycles)	PD

Abbreviations: 5-FU, 5-fluorouracil; Cape, capecitabine; CBCDA, carboplatin; CDDP, cisplatin; Epi, epirubicin; N/A, not applicable; NE, nonevaluable; PD, progressive disease; PR, partial response; RT, radiotherapy; SAE, serious adverse event; SD, stable disease.